❌

Reading view

Learning to Trust: How Humans Mentally Recalibrate AI Confidence Signals

arXiv:2603.22634v1 Announce Type: cross Abstract: Productive human-AI collaboration requires appropriate reliance, yet contemporary AI systems are often miscalibrated, exhibiting systematic overconfidence or underconfidence. We investigate whether humans can learn to mentally recalibrate AI confidence signals through repeated experience. In a behavioral experiment (N = 200), participants predicted the AI's correctness across four AI calibration conditions: standard, overconfidence, underconfidence, and a counterintuitive "reverse confidence" mapping. Results demonstrate robust learning across all conditions, with participants significantly improving their accuracy, discrimination, and calibration alignment over 50 trials. We present a computational model utilizing a linear-in-log-odds (LLO) transformation and a Rescorla-Wagner learning rule to explain these dynamics. The model reveals that humans adapt by updating their baseline trust and confidence sensitivity, using asymmetric learning rates to prioritize the most informative errors. While humans can compensate for monotonic miscalibration, we identify a significant boundary in the reverse confidence scenario, where a substantial proportion of participants struggled to override initial inductive biases. These findings provide a mechanistic account of how humans adapt their trust in AI confidence signals through experience.
  •  

Hypoxia-related and immune phenotype-related fusion model for non-invasive prognostication of hepatocellular carcinoma treated by TACE: a multicentre study

Gut. 2026 Mar 30:gutjnl-2025-337938. doi: 10.1136/gutjnl-2025-337938. Online ahead of print.

ABSTRACT

BACKGROUND: Survival outcomes after transarterial chemoembolisation (TACE) vary in hepatocellular carcinoma (HCC) patients, and existing prognostic scores and imaging models often lack generalisability and biological interpretability.

OBJECTIVE: To develop and validate a multimodal prognostication model for HCC that allows for a precise assessment of survival outcomes of HCC patients receiving TACE therapy.

DESIGN: This study enrolled 1448 HCC patients, including a TACE cohort (n=1349), a biomarker subset from a randomised trial (n=41), a single-cell RNA sequencing cohort and The Cancer Genome Atlas (TCGA) HCC cohort (n=50). Pre-treatment contrast-enhanced CT images were used to construct deep learning and conventional radiomic models. The early-fusion and late-fusion models (LFMs) were compared, and a clinical-radiologic model (CRM) was formed by integrating the better-performing LFM with clinical variables. Using TCGA data and single-cell transcriptomic profiles, the differences between high-score and low-score groups in tumour immune microenvironment, cellular functional states and key signalling pathways were investigated.

RESULTS: The CRM effectively stratified patients' survival across multiple independent cohorts and achieved more granular risk stratification than the existing clinical models. Multi-omic analyses revealed that in the LFM high-score group, myelocytomatosis oncogene was activated, epithelial-mesenchymal transition enhanced, glycolysis upregulated and hypoxia pathway activated. Single-cell transcriptomic data confirmed that virtually all cell types in high-risk patients scored high in hypoxia, and cytotoxic T cells had a reduced cytotoxic activity.

CONCLUSION: The CRM model can non-invasively predict the prognosis of HCC patients treated by TACE therapy.

PMID:41856522 | DOI:10.1136/gutjnl-2025-337938

  •  
❌